Heart failure oral therapies at discharge are associated with better outcome in acute heart failure: a propensity-score matched study

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F65269705%3A_____%2F18%3A00068517" target="_blank" >RIV/65269705:_____/18:00068517 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216224:14110/18:00102127

Výsledek na webu

<a href="https://onlinelibrary.wiley.com/doi/epdf/10.1002/ejhf.932" target="_blank" >https://onlinelibrary.wiley.com/doi/epdf/10.1002/ejhf.932</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1002/ejhf.932" target="_blank" >10.1002/ejhf.932</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Heart failure oral therapies at discharge are associated with better outcome in acute heart failure: a propensity-score matched study

Popis výsledku v původním jazyce

Aims Heart failure oral therapies (HFOTs), including beta-blockers (BB), renin-angiotensin system inhibitors (RASi) and mineralocorticoid receptor antagonists, administered before hospital discharge after acute heart failure (AHF) might improve outcome. However, concerns have been raised because early administration of HFOTs may worsen patient&apos;s condition. We hypothesized that HFOTs at hospital discharge might be associated with better post-discharge survival.&amp; para;&amp; para;Methods and results The study population was composed of 19 980 AHF patients from the GREAT registry. The primary and secondary and results outcomes were 90-day and 1-year all-cause mortality, respectively. Survival was estimated with univariate and covariate-adjusted Cox proportional hazards regression models for the whole population and after propensity-score matching. HFOTs at discharge were consistently associated with no excess mortality in the unadjusted and adjusted analyses of the whole and matched cohorts. In the matched cohort, BB and RASi at discharge were associated with lower 90-day mortality risks compared to the respective untreated groups [hazard ratio (HR) 0.56, 95% confidence interval (CI) 0.46-0.69; and HR 0.53, 95% CI 0.42-0.66, respectively]. The favourable associations of BB and RASi at discharge with 90-day mortality were present in many subgroups including patients with reduced or preserved left ventricular ejection fraction and persisted up to 1 year after discharge. The combination of RASi and BB was associated with an even lower risk of death than RASi or BB alone.&amp; para;&amp; para;Conclusions Administration of HFOTs at hospital discharge is associated with better survival of AHF patients.

Název v anglickém jazyce

Heart failure oral therapies at discharge are associated with better outcome in acute heart failure: a propensity-score matched study

Popis výsledku anglicky

Aims Heart failure oral therapies (HFOTs), including beta-blockers (BB), renin-angiotensin system inhibitors (RASi) and mineralocorticoid receptor antagonists, administered before hospital discharge after acute heart failure (AHF) might improve outcome. However, concerns have been raised because early administration of HFOTs may worsen patient&apos;s condition. We hypothesized that HFOTs at hospital discharge might be associated with better post-discharge survival.&amp; para;&amp; para;Methods and results The study population was composed of 19 980 AHF patients from the GREAT registry. The primary and secondary and results outcomes were 90-day and 1-year all-cause mortality, respectively. Survival was estimated with univariate and covariate-adjusted Cox proportional hazards regression models for the whole population and after propensity-score matching. HFOTs at discharge were consistently associated with no excess mortality in the unadjusted and adjusted analyses of the whole and matched cohorts. In the matched cohort, BB and RASi at discharge were associated with lower 90-day mortality risks compared to the respective untreated groups [hazard ratio (HR) 0.56, 95% confidence interval (CI) 0.46-0.69; and HR 0.53, 95% CI 0.42-0.66, respectively]. The favourable associations of BB and RASi at discharge with 90-day mortality were present in many subgroups including patients with reduced or preserved left ventricular ejection fraction and persisted up to 1 year after discharge. The combination of RASi and BB was associated with an even lower risk of death than RASi or BB alone.&amp; para;&amp; para;Conclusions Administration of HFOTs at hospital discharge is associated with better survival of AHF patients.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30201 - Cardiac and Cardiovascular systems

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2018

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

European Journal of Heart Failure

ISSN

1388-9842

e-ISSN

—

Svazek periodika

20

Číslo periodika v rámci svazku

2

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

10

Strana od-do

345-354

Kód UT WoS článku

000429044500022

EID výsledku v databázi Scopus

2-s2.0-85028469590